Tag Archives: clinical trials

June, 2017

October, 2016

August, 2016

July, 2016

June, 2016

  • 8 June

    Biogen’s Multiple Sclerosis Drug Misses Main Goal in its Phase 2 Study

    CAMBRIDGE, Mass.–(BUSINESS WIRE)–Today Biogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent …